^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Pancreatic Cancer
    Drug:evofosfamide (IMGS-101) (Alkylating agent)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Merck (MSD) Press Release
    Title:

    Merck Receives FDA Fast Track Designation for Evofosfamide for Treatment of Patients Living With Advanced Pancreatic Cancer

    Published date:
    05/12/2015
    Excerpt:
    Merck...announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development of evofosfamide (previously known as TH-302), administered in combination with gemcitabine, for the treatment of previously untreated patients with metastatic or locally advanced unresectable pancreatic cancer.
    Secondary therapy:
    gemcitabine